UM

Browse/Search Results:  1-4 of 4 Help

Selected(0)Clear Items/Page:    Sort:
Investigational hypoxia-activated prodrugs: Making sense of future development Journal article
Current Drug Targets, 2019,Volume: 20,Issue: 6,Page: 668-678
Authors:  Su,Min Xia;  Zhang,Le Le;  Huang,Zhang Jian;  Shi,Jia Jie;  Lu,Jin Jian
Favorite |  | TC[WOS]:2 TC[Scopus]:3 | Submit date:2021/03/02
Dna alkylating agents  Hypoxia-activated prodrug  Patient selection  Reductase activity  Targeted drugs  Topoisomerase II inhibitors  
Hybrid Nanomedicine Fabricated from Photosensitizer-Terminated Metal-Organic Framework Nanoparticles for Photodynamic Therapy and Hypoxia-Activated Cascade Chemotherapy Journal article
SMALL, 2018,Volume: 15,Issue: 4
Authors:  Zhimei He;  Yunlu Dai;  Xiangli Li;  Dan Guo;  Yijing Liu;  Xiaolin Huang;  Jingjing Jiang;  Sheng Wang;  Guizhi Zhu;  Fuwu Zhang;  Lisen Lin;  Jun‐Jie Zhu;  Guocan Yu;  Xiaoyuan Chen
Favorite |  | TC[WOS]:50 TC[Scopus]:52 | Submit date:2020/05/13
Banoxantrone  Cascade Therapy  Hypoxia-activated Prodrugs  Nanoscale Metal-organic Frameworks  Photodynamic Therapy  
Hybrid Nanomedicine Fabricated from Photosensitizer‐Terminated Metal–Organic Framework Nanoparticles for Photodynamic Therapy and Hypoxia‐Activated Cascade Chemotherapy Journal article
small, 2018,Volume: 15,Issue: 4
Authors:  Zhimei He;  Yunlu Dai;  Xiangli Li;  Dan Guo;  Yijing Liu;  Xiaolin Huang;  Jingjing Jiang;  Sheng Wang;  Guizhi Zhu;  Fuwu Zhang;  Lisen Lin;  Jun‐Jie Zhu;  Guocan Yu;  Xiaoyuan Chen
Favorite |  | TC[WOS]:0 TC[Scopus]:52 | Submit date:2019/01/28
Banoxantrone  Cascade Therapy  Hypoxia‐activated Prodrugs  Nanoscale Metal–organic Frameworks  Photodynamic Therapy  
Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development Journal article
Current Drug Targets, 2018,Volume: 20
Authors:  Min-Xia Su;  Le-Le Zhang;  Zhang-Jian Huang;  Jia-Jie Shi;  Jin-Jian Lu
Favorite |  | TC[WOS]:0 TC[Scopus]:3 | Submit date:2019/01/14
Hypoxia-activated Prodrug  Topoisomerase Ii Inhibitors  Dna Alkylating Agents  Targeted Drugs  Reductases Activity  Patient Selection  Clinical Progress